Agilent Technologies A

Phio Pharmaceuticals Corp. (Nasdaq: $PHIO ) President and Chief Executive Officer Robert Bitterman outlined the next steps for PH-762 at the H.C. Wainwright 28th Annual Global Investment Conference. In its September 14 update, Phio announced it had submitted an FDA meeting request and briefing package following Phase 1b completion, including plans for a Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma. Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/phio-pharmaceuticals Phio's development priorities include the planned PH-762 study and the broader INTASYL® portfolio: • The FDA briefing package includes the scientific rationale, proposed study design and pharmacokinetic strategy for the next planned Phase 2b study • Clinical supplies are expected to be available in the first quarter of 2027 • The dosing phase of a nonclinical toxicology study is complete, with final activities supporting the next phase of development expected to be completed in the first quarter of 2027 • PH-894, the second development program, targets BRD4 and has completed IND-enabling studies • Cash and cash equivalents were $13.0 million at June 30, 2026 Bitterman closed the session with this summary of the company: "And so with that, I leave you with Phio Pharmaceuticals, a company that is finding out how to make immune cells more effective in killing cancer cells, and doing so effectively in our first study." Watch the full presentation: https://journey.ct.events/view/5bf7a12c-0681-4ee5-9849-694423f35dfd Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. PH-762 is a potential non-surgical treatment for skin cancers. Learn more at https://phiopharma.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $A $R $A $XBI $ARKG

$A New Research Finds AI Adoption Accelerating in Workplace Safety https://marketwirenews.com/stock/a/news/new-research-finds-ai-adoption-accelerating-in-workp-6781439402541515.html?utm_source=stocktwits

$A Omdia: "Sovereign AI" Claims Often Fail to Match Reality, Putting Enterprises at Risk https://marketwirenews.com/stock/a/news/omdia-sovereign-ai-claims-often-fail-to-match-realit-5583864040616048.html?utm_source=stocktwits

$A 💪

$A bounced off August highs and held. Still like this name a lot

$A is now extended with 3 green bricks.

This is the Industry Chart for $A

$A A (Weekly & 195-Min Renko) System Status: GO (2nd Green Brick Confirmed) Setup Trigger (195-Min Renko) 2nd Green Brick Confirmed: Printed cleanly at $171.27, holding above PSAR support ($166.08) and 20-EMA ($165.09). StochRSI: Hooking upward out of oversold territory (0.301), signaling fresh momentum expansion. Extension Filter: Price is safely within range at ~3.7% above the 195-min 20-EMA. Higher-Timeframe Support (Weekly) Weekly RSI(14): 69.02, reflecting robust long-term buying pressure without being overbought. Macro Structure: SCTR sits at an elite 95.0. Price cleanly holds above rising 10-EMA ($160.18) and 20-EMA ($150.34) with weekly Renko back in green. The Takeaway: Agilent satisfies all primary system criteria for a high-probability long entry. Clear runway to earnings on November 25, 2026. Execution Checklist Entry: Buy zone ~$171.27–$172.50 Hard Stop Loss: $166.00 (below 195-min PSAR support) Invalidation: Close position if 195-min red brick prints below $166.08